

## antiviral and associated therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
chloroquine and derivatives	15 studies <sup>1</sup>		inconclusive results for : deaths ; confirmed COVID (any severity) ; conversion to SARS-CoV- 2–positive status via NP swab ; death or ventilation ; hospitalization ; symptomatic Covid-19 ; asymptomatic COVID case ; infection (PCR positive symptomatic or not) ; serious adverse events ; adverse events		
ivermectin	4 studies <sup>2</sup>		inconclusive results for : deaths ; serious adverse events ; adverse events	suggested 73	
bromhexine	1 study <sup>3</sup>		inconclusive results for : deaths ; hospitalization ; new illness compatible with Covid-19 ; ICU admission		
nirmatrelvir / ritonavir (Paxlovid)	1 study <sup>4</sup>		-		

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

## Notes

<sup>1</sup>Abella, 2020 (NCT04329923) ; EPICOS (Polo), 2022 ( ) ; HERO-HCQ (Naggie), 2021 (NCT04334148) ; Rojas-Serrano, 2021 (NCT04318015) ; Seet (HCQ), 2021 (NCT04446104) ; Syed, 2021 (NCT04359537) ; Barnabas RV, 2020 (NCT04328961) ; BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 (NCT04304053) ; COVID PREP HCQ (2x week, Rajasingham), 2020 (NCT04328467) ; COVID-PEP-Post exposure (Boulware), 2020 (NCT04308668) ; Grau-Pujol, 2020 (NCT04331834) ; PATCH-cohort 3 PreP (Abella), 2020 (NCT04329923) ; Gendelman, 2020 ( ) ; Rentsch, 2020 ( ) ; EPI-PHARE, 0 ( )

<sup>2</sup>Ivercar-Tuc, 2021 (NCT04701710) ; Seet 2021, 2021 (NCT04446104) ; NCT04422561 (Shouman), 2020 (NCT04422561) ; Behera, 2020 ( )

<sup>3</sup>Mikhaylov, 2021 (NCT04405999)

<sup>4</sup>EPIC PEP, 2022 (NCT05047601)